Hilgert I, Cudlín J, Steinerová N, Vanĕk Z
Folia Biol (Praha). 1977;23(2):99-109.
Both isomeric monohydroxyanthraquinones (1a, b), three dihydroxyanthraquinones (alizarin 1c, chrysazin 1d, and anthraflavin 1e) and corresponding acetylated (2) and free (3) beta-D-glucosides were screened for antitumour and immunosuppressive activity. Furthermore, four O-acetyl and O-benzyl derivatives of alizarin (5a--d) were tested. Antitumour activity was judged by the inhibition of growth of syngeneic tumours in the treated recipients and immunosuppressive activity by the effect on tumour growth or on skin graft survival in pretreated allogeneic recipients; as standard of reference served the activity of certain cancerostatic or immunosuppressive drugs used in clinical practice. 1-Hydroxyanthraquinone (1a), alizarin (1c), chrysazin (1d), acetylated glucoside of 2-hydroxyanthraquinone (2b), 2-benzylalizarin (5c), and 1-acetyl-2-benzylalizarin (5d) were found to exhibit antitumour activity. Distinct immunosuppressive activity was detected in alizarin (1c), acetylated glucoside of 1-hydroxyanthraquinone (2a), acetylated glucoside of 2-hydroxyanthraquinone (2b), acetylated glucoside of chrysazin (2d), 2-acetylalizarin (5a), and 1-acetyl-2-benzylalizarin (5d). The group of hydroxyanthraquinone glucodises (3a--3d) exhibited neither antitumour nor immunosuppressive activity.
对两种异构的单羟基蒽醌(1a,b)、三种二羟基蒽醌(茜素1c、柯桠素1d和蒽黄素1e)以及相应的乙酰化(2)和游离(3)β - D - 葡萄糖苷进行了抗肿瘤和免疫抑制活性筛选。此外,还测试了茜素的四种O - 乙酰基和O - 苄基衍生物(5a - d)。通过观察处理后的同基因肿瘤在受体中的生长抑制情况来判断抗肿瘤活性,通过观察对预处理的异基因受体中的肿瘤生长或皮肤移植存活的影响来判断免疫抑制活性;以临床实践中使用的某些抗癌或免疫抑制药物的活性作为参考标准。发现1 - 羟基蒽醌(1a)、茜素(1c)、柯桠素(1d)、2 - 羟基蒽醌的乙酰化葡萄糖苷(2b)、2 - 苄基茜素(5c)和1 - 乙酰基 - 2 - 苄基茜素(5d)具有抗肿瘤活性。在茜素(1c)、1 - 羟基蒽醌的乙酰化葡萄糖苷(2a)、2 - 羟基蒽醌的乙酰化葡萄糖苷(2b)、柯桠素的乙酰化葡萄糖苷(2d)、2 - 乙酰基茜素(5a)和1 - 乙酰基 - 2 - 苄基茜素(5d)中检测到明显的免疫抑制活性。羟基蒽醌葡萄糖苷组(3a - 3d)既没有抗肿瘤活性也没有免疫抑制活性。